NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
49 hedge funds and large institutions have $6.65M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
29% less capital invested
Capital invested by funds: $9.3M → $6.65M (-$2.65M)
81% less call options, than puts
Call options by funds: $44K | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.05M |
| 2 |
B
Bailard
Foster City,
California
|
+$222K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$104K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$66.6K |
| 5 |
Renaissance Technologies
New York
|
+$43.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$369K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$75K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58.1K |
| 4 |
GBA
Garrison Bradford & Associates
New York
|
-$25.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -3 | Closed |
|
|
PCA
52
Peddock Capital Advisors
Braintree,
Massachusetts
| – | -$2K | -1 | Closed |
|
NBSE Hedge Fund Activity: Q4 2016 in Review
49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2016, worth a combined $6.65M — down 29% from $9.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NBSE positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.05M. The largest seller was Vanguard Group, cutting an estimated $369K.
- 49 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2016, up from 47 in Q3 2016.
- Funds reported $6.65M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2016, down 29% quarter-over-quarter.
- 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2016 and 3 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2016 was Sabby Management, an estimated $3.05M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2016 was Vanguard Group, an estimated $369K sold.
Based on aggregated 13F filings for Q4 2016.